Title : Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease.

Pub. Date : 2020 May 1

PMID : 32249610






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD). Metformin protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus
2 Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD). Metformin protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus
3 In addition, treatment with metformin was also able to activate kidney AMPK and therefore improve mitochondrial biogenesis. Metformin protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus
4 It was concluded that metformin can arrest the progression of established kidney disease in the Nx model, likely via the activation of AMPK. Metformin protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus